The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

SBIR Reauthorization Likely: Uncertain Improvements for VC-Backed Companies

SBIR bannerThe SBIR program in the U.S. looks to be heading toward reauthorization with increased funding amounts — up to $250,000 in Phase One (up from $100,000) and up to $2,000,000 in Phase Two (up from $750,000). 

VC-backed companies are not eligible under the current program, but that should change.  The Senate version of the bill allows some funding to VC-backed companies, but caps the percentage of grants that can go to VC-backed firms at 8%.  The House version doesn’t cap the amount, but implements some other restrictions to prevent abuse: no SBIR funding to companies with over 500 employees, or that are majority-owned by one venture firm, or that have too large a stake held by “corporate-owned venture firms.”

Bookmark and Share

About these ads

One response to “SBIR Reauthorization Likely: Uncertain Improvements for VC-Backed Companies

  1. Pingback: Senate Action on Small Business Innovation This Week? « The Cross-Border Biotech Blog

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Follow

Get every new post delivered to your Inbox.

Join 126 other followers